Business Wire

New Data from Esketamine Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent

Share

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from two pivotal Phase 3 clinical studies (ASPIRE I & II) to evaluate the efficacy and safety of esketamine nasal spray in addition to comprehensive standard of care (SOC) in adult patients with major depressive disorder who have active suicidal ideation with intent. These studies were presented at the 32nd European College of Neuropsychopharmacology (ECNP), taking place September 7–10 in Copenhagen.

The double-blind, randomised, placebo-controlled, multicentre studies both met their respective primary efficacy endpoint, which was a reduction in depressive symptoms at 24 hours after the first dose, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). In both studies, esketamine nasal spray 84 mg plus SOC showed clinically meaningful and statistically significant superiority (p=0.006) over placebo plus SOC in rapidly reducing symptoms of major depressive disorder.[i] [ii]

In the ASPIRE I & II trials, esketamine nasal spray plus SOC was generally well-tolerated with no new safety signals. The safety profile observed was consistent across the two Phase 3 studies in patients with major depressive disorder who have active suicidal ideation with intent, as well as previous studies of esketamine in patients with treatment-resistant depression. In the esketamine plus SOC group, the most common adverse events (≥10%), with a frequency of more than twice that of the placebo plus SOC group, were dizziness, dissociation, nausea, somnolence, vision blurred, vomiting, paresthesia, increased blood pressure and sedation.[i] [ii]

“These data are particularly important because patients with major depressive disorder presenting with active suicidal ideation with intent constitute a psychiatric emergency that requires immediate intervention,” said Carla Canuso, M.D., Senior Director, Clinical Research, Janssen Research & Development, LLC, leading the ASPIRE I & II studies. “Although currently available antidepressants are effective for many patients, their onset of effect can take four to six weeks,[iii] offering limited benefit to those in urgent need.”

In these studies, both esketamine plus comprehensive SOC and placebo plus comprehensive SOC resulted in improvement in severity of suicidality as measured by the revised Clinical Global Impression of Severity of Suicidality (CGI-SS-R) at 24 hours after the first dose. The treatment difference between the two groups on this secondary endpoint was not statistically significant. This may be due to the substantial beneficial effects of comprehensive SOC utilised in the clinical trial, including the impact of inpatient psychiatric hospitalisation in diffusing the acute suicidal crisis in subjects in both treatment groups.

The 456 patients who participated in the trials had moderate-to-severe major depressive disorder. More than 85 percent were rated by clinicians to be moderately to extremely suicidal. In order to safely and ethically conduct the study in this vulnerable patient population, all patients were treated with the comprehensive standard of care, which included initial hospitalisation and a newly initiated or optimized antidepressant regimen.

“These are the first global clinical studies in this severely ill patient population, who are typically excluded from antidepressant treatment studies,” said Husseini K. Manji, M.D., Global Head, Neuroscience Therapeutic Area, Janssen Research & Development, LLC. “At Janssen, we are committed to continued clinical research excellence that leads to discovery and development of new and more effective treatment options for people living with mental illnesses, including severe mood disorders. The esketamine nasal spray development program is a demonstration of that commitment and our recognition of the great unmet need among individuals with major depressive disorder who experience suffering from a serious, biologically based disease which has a significant negative impact on various aspects of life.”

Study Details: Reduction in Depressive Symptoms
At 24 hours after the first dose of study medication in ASPIRE I & II, the mean difference observed in the reduction of depressive symptoms between the esketamine plus SOC group and the placebo plus SOC group was 3.8 points and 3.9 points, respectively, as measured by the MADRS.

The benefit of esketamine plus SOC on symptoms of major depressive disorder was apparent at four hours after the first dose. Between four hours and 25 days, both the esketamine and placebo groups continued to improve, and the magnitude of difference between the groups generally remained throughout the 25-day double-blind period. In the ASPIRE I & II trials, 54 percent and 47 percent, respectively, of the esketamine plus SOC group achieved remission (MADRS score ≤ 12) by the end of the double-blind period. The clinical improvement during the double-blind period was maintained over the nine-week follow-up period in both treatment groups.

About Esketamine
Esketamine is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor. It has a novel mechanism of action, meaning it works differently than currently available therapies for major depressive disorder.[iv] [v] [vi] [vii] [viii]

Esketamine nasal spray in conjunction with a newly initiated antidepressant is approved in the US for the treatment of treatment-resistant depression (TRD) and has been submitted for Health Authorities review for TRD in other markets around the world, including Europe.[ix] The FDA granted Breakthrough Therapy designation to esketamine nasal spray for treatment-resistant depression in November 2013 and for reduction of major depressive disorder symptoms in patients with active suicidal ideation in August 2016.[x]

Janssen submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for the esketamine treatment-resistant depression indication in Europe in October 2018.[xi]

About Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Major depressive disorder affects nearly 300 million people of all ages globally and is the leading cause of disability worldwide.[xii] Individuals with major depressive disorder experience suffering from a serious, biologically based disease which has a significant negative impact on all aspects of life, including quality of life and function.

Depression is one of the most relevant risk factors associated with suicide.[xiii]

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Janssen Research & Development, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Learn more at www.janssen.com/emea. Follow us at www.twitter.com/JanssenEMEA.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development of esketamine. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen Cilag International NV, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of healthcare products and services; changes to applicable laws and regulations, including global healthcare reforms; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

###

[i] Fu DJ, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients at imminent risk for suicide. ASPIRE-1 study. Poster P323 presented at ECNP 2019, 7–10 September, Copenhagen, Denmark.
[ii] Ionescu DF, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients at imminent risk for suicide. ASPIRE-2 study. Poster P607 presented at ECNP 2019, 7–10 September, Copenhagen, Denmark.
[iii] Haggerty, J. PsychCentral.com. An Overview of Depression Treatment Options. Available at: https://psychcentral.com/lib/an-overview-of-depression-treatment-options/. (last accessed September 2019).
[iv] Popova V, et al. Am J Psychiatry 2019. doi: 10.1176/appi/ajp.2019.19020172 [Epub ahead of print].
[v] Daly E, et al. JAMA Psychiatry 2019. doi: 10.1001/jamapsychiatry.2019.1189 [Epub ahead of print].
[vi] Wajs E, et al. Poster T67 presented at ASCP 2018, 29 May–01 June, Miami, Florida.
[vii] Fedgchin M, et al. Int J Neuropsychopharmacol. 2019 Jul 10. pii: pyz039. doi: 10.1093/ijinp/pyz039. [Epub ahead of print]
[viii] Ochs-Ross R, et al. Poster W27 presented at ASCP 2018, 19 May–01 June, Miami, Florida.
[ix] Janssen. Press Release March 2019. Janssen Announces U.S. FDA Approval of SPRAVATO™ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief. Available at: https://www.janssen.com/janssen-announces-us-fda-approval-spravato-esketamine-ciii-nasal-spray-adults-treatment-resistant. (last accessed September 2019).
[x] Johnson & Johnson Ltd. Press Release August 2016. Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Major Depressive Disorder with Imminent Risk for Suicide. Available at: https://www.jnj.com/media-center/press-releases/esketamine-recieves-breakthrough-therapy-designation-from-us-food-and-drug-administration-for-major-depressive-disorder-with-imminent-risk-of-suicide. (last accessed September 2019).
[xi] Johnson & Johnson Ltd. Press release October 2018. Janssen Submits European Marketing Authorisation Application for Esketamine Nasal Spray for Treatment-Resistant Depression. Available at: https://www.jnj.com/janssen-submits-european-marketing-authorisation-application-for-esketamine-nasal-spray-for-treatment-resistant-depression. (last accessed September 2019).
[xii] World Health Organization. Depression. Available at: https://www.who.int/en/news-room/fact-sheets/detail/depression. (last accessed September 2019).
[xiii] Bachmann S. Int J. Environ. Res. Public Health 2018 Jul 6; 15(7). Pii: E1425. doi: 10.3390/ijerph15071425.

EM-16761
September 2019

Contact information

Media contact:
Cristiana Maria
Mobile: +32 473 11 28 10
cmaria@its.jnj.com

Investor Relations:
Christopher DelOrefice
Phone: +1 732-524-2955
Lesley Fishman
Phone:+1 732-524-3922

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meet Global Exhibitors and Hear from World-Renowned Speakers at CHTF201914.11.2019 04:00:00 EETPress release

The 21st China Hi-Tech Fair (CHTF2019), themed “invigorating the Great Bay Area through opening up and innovation,” opened on November 13-17, 2019 in Shenzhen, China. Visitors will meet leading local and global hi-tech enterprises as well as Nobel laureate speakers. Featuring the technological achievements in the Guangdong-Hong Kong-Macau Greater Bay Area, CHTF2019 created an online VR exhibition hall for key exhibitors, especially enterprises from the Area, to help them reach a larger audience apart from on-site visitors. Chamtent Technology (Booth: 2G69), focusing on smart household products, has developed a series of environment-friendly products such as smart trash cans, as well as the HyperLink Automatic Waste Recycled System to be applied in modern residential communities to make life more effective. ISUKE Technology (Booth: 2D31) focuses on health management for both professional healthcare institutions and individuals. Its innovative health information collection devices (inclu

Juan Carro Arbelo Appointed as Regional Manager for Insurance, Iberia13.11.2019 22:00:00 EETPress release

Starr Insurance Companies today announced the appointment of Juan Carro Arbelo as Regional Manager for Insurance, Iberia, subject to regulatory approval. Mr. Carro is responsible for the development of Starr’s commercial lines presence across the Iberian Peninsula, effective November 4, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191113005709/en/ (Photo: Business Wire) “Juan brings more than 22 years of insurance industry experience working on both the brokerage and carrier sides of the business,” stated Maurice R. Greenberg, Chairman and CEO, Starr Insurance Companies. “His extensive background in developing and establishing lines of business will aid in growing new channels for Starr across Iberia.” The new role strengthens Starr’s European operations, which now includes the UK, Benelux countries, Central and Eastern Europe and the Iberian Peninsula. The European region offers a wide breadth of Starr’s insurance p

SNCF Selects Klas Telecom TRX R6 for French National Rail Network13.11.2019 20:00:00 EETPress release

Klas Telecom today announced that, together with their French partner Seolane Innovation, they have entered into an agreement with France’s national rail operator, SNCF to supply the TRX R6 Connected Transportation Platform for implementation on board SNCF’s trains. This agreement comes as the result of a highly competitive public tender in which SNCF sought to acquire an onboard connectivity solution to provide improved operational and passenger-centric services. Julien Baratier, the Project Manager for SNCF commented, "Through this tender process, we sought to develop our onboard technical solution to fulfil our customer requirements in terms of train connectivity and onboard services. Although new partners for us, Klas Telecom and Seolane have demonstrated their technical commitment by offering a modular, flexible and performing solution. We are very excited to now be working together on a first rollout on regional trains to support a CCTV service." Wilfrid Rouger, CEO of Seolane In

U.S. Ambassador Johnson and UK’s Sir Nicholas Soames to join Bermuda Premier at Executive Forum in London13.11.2019 19:17:00 EETPress release

The United States Ambassador to the United Kingdom (UK), Robert Wood Johnson, and the UK’s Rt. Hon. Sir Nicholas Soames, former defence minister and former Conservative Member of Parliament for Mid Sussex, will join Bermuda’s Premier, the Hon. E. David Burt, JP, MP, at an Executive Forum in London this month to highlight the historic and successful economic relationship that exists between Bermuda, the U.S. and the UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191113005627/en/ Bermuda Executive Forum London 2019 opening panel. (Photo: Business Wire) The keynote conversation between Ambassador Johnson, Sir Nicholas Soames and the Premier will explore the implications of global trends, address key challenges from Brexit to U.S. tax reform, and shed light on new opportunities to further develop economic ties. The discussion will be moderated by Fiona Luck, a Non-Executive Director on the Lloyd’s of London Franchise Board,

Advance Auto Parts, Blue Cross NC, Emory Healthcare, Johnsonville, Parkview Health, and Royal Bank of Scotland Receive Planview Vision Awards13.11.2019 19:01:00 EETPress release

Over 700 attendees came together at Planview Horizons 2019 to connect, collaborate, and celebrate with their industry peers. This year, Advance Auto Parts, Blue Cross NC, Emory Healthcare, Johnsonville, Parkview Health, and Royal Bank of Scotland were the recipients of Planview Vision Awards for transformational leadership and excellence. “There are many remarkable business transformation journeys that our customers have undertaken leveraging Planview solutions,” said Marc Cannon, Planview chief customer officer. “We were honored at this year’s Planview Horizons to celebrate these six visionary organizations for their commitment to, and success in, achieving their strategic goals.” Advance Auto Parts To address the industry trends around increased use of ridesharing, electric cars, and autonomous vehicles, a few “hidden innovators” at Advance Auto Parts set out to generate and collaborate on new ideas that would disrupt the market and delight their customers. With Planview Spigit™, Adv

Mercatus Selected as Finalist for REFI US Award for Portfolio Management13.11.2019 17:00:00 EETPress release

Mercatus, the data and technology platform for private market investors, today announced it has been shortlisted as a finalist for the 2019 REFI US Award for Portfolio Management. The REFI US Awards reward real estate private equity funds and service providers for outstanding performance and overall excellence. “We understand the unique challenges of real estate investing in harnessing very disparate data for critical risk and performance insights,” said Haresh Patel, CEO of Mercatus. “We purposefully built a modern data-driven architecture that starts at the site- and asset-level and then rolls up to fund/portfolio levels. We believe it’s the only way to truly understand and measure each investment. It’s very rewarding to be recognized by REFI US for the innovation we’ve brought to this sector.” REFI US award winners are selected through a rigorous two-stage judging process using both performance metrics as well as qualitative factors. Factors used by judges in the “PropTech” category

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom